News

LumiThera’s PBM is the only device that has demonstrated meaningful vision improvement compared to baseline for people living ...
Alcon has inked a deal to acquire LumiThera and its light-based therapy for dry age-related macular degeneration, which obtained a groundbreaking FDA clearance late last year. | LumiThera's approach ...
Alcon to Acquire LumiThera and its Photobiomodulation Device for the Treatment of Early and Intermediate Dry Age-Related Macular Degeneration (AMD) ...
Sean Clark, the VP and general manager of Alcon’s Global Surgical Franchise, added: “Dry AMD is an area of significant unmet ...
Alcon AG plans to acquire Lumithera Inc., adding its photobiomodulation (PBM) device designed to treat early and intermediate dry age-related macular degeneration (AMD) to the Alcon portfolio. The ...
This is a developing news story. Please check back soon for updates. Alcon will acquire LumiThera, including its ...
Alcon to Acquire LumiThera and Its Photobiomodulation Device for the Treatment of Early and Intermediate Dry Age-Related Macular Degeneration (AMD) Jul. 07, 2025 8:00 AM ET Alcon Inc. (ALC) ...
GENEVA - Alcon (SIX/NYSE:ALC), a prominent $43.6 billion healthcare equipment player with robust financials and a "GOOD" overall health score according to InvestingPro, announced Monday its intention ...
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced its intention to acquire LumiThera, Inc., a leader in light-based innovations for ...
(RTTNews) - Alcon (ALC) announced its intention to acquire LumiThera, Inc., and its PBM device for the treatment of early and intermediate dry AMD. LumiThera is an ophthalmic medical device ...
Monday announced its intention to acquire LumiThera and its PBM device for the treatment of early and intermediate dry AMD.
GENEVA - Alcon (SIX/NYSE:ALC), a prominent $43.6 billion healthcare equipment player with robust financials and a "GOOD" overall health score according to InvestingPro, announced Monday its ...